Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?

Kraker, Marlieke E A de; Stewardson, Andrew J.; Harbarth, Stéphan Juergen

doi:10.1371/journal.pmed.1002184

Cited by 1,173 publications

(818 citation statements)

References 8 publications

Supporting

Mentioning

795

Contrasting

Unclassified

Order By: Relevance

“…Current estimates of the associated burden vary greatly depending on the method of data collation and analysis [1], but a recent report commissioned by the United Kingdom government estimated that, by 2050, 10 million people will die every year due to antimicrobial resistance unless appropriate countermeasures are taken [2]. A range of infectious microbial pathogens are already resistant to most classes of clinically usable antibiotics, strongly reducing the choices of alternative treatments, that sometimes are simply non-existent [3,4].…”

Section: The Rising Tide Of Antimicrobial Resistancementioning

confidence: 99%

Antimicrobial Dendrimeric Peptides: Structure, Activity and New Therapeutic Applications

Scorciapino

Serra

Manzo

et al. 2017

IJMS

View full text Add to dashboard Cite

Microbial resistance to conventional antibiotics is one of the most outstanding medical and scientific challenges of our times. Despite the recognised need for new anti-infective agents, however, very few new drugs have been brought to the market and to the clinic in the last three decades. This review highlights the properties of a new class of antibiotics, namely dendrimeric peptides. These intriguing novel compounds, generally made of multiple peptidic sequences linked to an inner branched core, display an array of antibacterial, antiviral and antifungal activities, usually coupled to low haemolytic activity. In addition, several peptides synthesized in oligobranched form proved to be promising tools for the selective treatment of cancer cells.

show abstract

Section: The Rising Tide Of Antimicrobial Resistancementioning

confidence: 99%

Antimicrobial Dendrimeric Peptides: Structure, Activity and New Therapeutic Applications

Scorciapino

Serra

Manzo

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…We have overused and misused antibiotics and antifungals not only to treat humans, but also to support food production of animals and plants for our everincreasing population. While this assertion has been disputed [9], it is nevertheless clear that the threat from infectious diseases is not decreasing, but rather it is increasing. This means that the evolution of antimicrobial drug resistance can be fast in all classes of pathogens (bacteria, fungi and parasites) [1,[5][6][7].…”

Section: Challenges In Treating Infectious Diseasesmentioning

confidence: 99%

Central metabolic interactions of immune cells and microbes: prospects for defeating infections

Traven

Naderer

2019

EMBO Reports

View full text Add to dashboard Cite

Antimicrobial drug resistance is threatening to take us to the “pre‐antibiotic era”, where people are dying from preventable and treatable diseases and the risk of hospital‐associated infections compromises the success of surgery and cancer treatments. Development of new antibiotics is slow, and alternative approaches to control infections have emerged based on insights into metabolic pathways in host–microbe interactions. Central carbon metabolism of immune cells is pivotal in mounting an effective response to invading pathogens, not only to meet energy requirements, but to directly activate antimicrobial responses. Microbes are not passive players here—they remodel their metabolism to survive and grow in host environments. Sometimes, microbes might even benefit from the metabolic reprogramming of immune cells, and pathogens such as Candida albicans, Salmonella Typhimurium and Staphylococcus aureus can compete with activated host cells for sugars that are needed for essential metabolic pathways linked to inflammatory processes. Here, we discuss how metabolic interactions between innate immune cells and microbes determine their survival during infection, and ways in which metabolism could be manipulated as a therapeutic strategy.

show abstract

“…Indeed a critique of the O'Neill () report warned that using unreliable numbers could potentially undermine, rather than support, the fight against a post‐antibiotic era (de Kraker et al . ) There is always a danger that promoting a “Project Fear” style message may be counterproductive.…”

Section: Introductionmentioning

confidence: 99%

Prescription rebellion: reduction of antibiotic use by small animal veterinarians

Allerton

Jeffery

2020

J of Small Animal Practice

View full text Add to dashboard Cite

Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?

Abstract: Marlieke de Kraker and colleagues reflect on the need for better global estimates for the burden of antimicrobial resistance.

Cited by 1,173 publications

References 8 publications

Antimicrobial Dendrimeric Peptides: Structure, Activity and New Therapeutic Applications

Antimicrobial Dendrimeric Peptides: Structure, Activity and New Therapeutic Applications

Central metabolic interactions of immune cells and microbes: prospects for defeating infections

Prescription rebellion: reduction of antibiotic use by small animal veterinarians

Contact Info

Product

Resources

About